Impact of the PACIFIC Study Updated Analysis

Transcript:Nicolas Girard, MD: In the updated analysis of PACIFIC, we now have a clear view of the progression pattern during durvalumab consolidation. The first point is that we have a reduction in the risk of disease progression, and this is related to a reduction in the risk of distant metastasis. Meaning that we have a decrease in the incidence of brain metastasis and lung metastasis, and we have a global effect of durvalumab on this time to distant metastasis. And this is what we have actually in the clinic. We know that after chemoradiation, we have a higher risk of recurrence in the brain, in the lung, in the liver